Gelasia Tomentosa Butanolic Extract Exhibits Antiproliferative Activity Against MCF-7 Breast Cancer Cells: Mechanistic Insights into Synergistic EGFR and TOP2A Targeting
Objective: This preliminary study investigated the in vitro cytotoxicity and selectivity of the Gelasia tomentosa butanolic extract (Gt-BuOH) against MCF-7 breast cancer cells, using HFF fibroblasts as a non-malignant control, and explored associations between treatment and changes in p-EGFR, TOP2A, and TNF-α protein levels. Molecular docking was performed to generate hypotheses. Materials and Methods: Gt-BuOH (13.6% w/w fatty extract) was prepared by liquid-liquid partitioning of 650 g of powdered aerial parts. Chemical composition was characterized by GC-MS with retention index matching; compounds with similarity index ≥70% were tentatively identified. Cytotoxicity was determined using the MTT assay for cell viability at 0.1–1000 µg/mL in the MCF-7 cancer cell line and healthy HFF cells after 24 h and 72 h of incubation. Quantification of p-EGFR, TOP2A, and TNF-α was performed by ELISA. Key phytoconstituents were docked against these targets, with binding affinities estimated using AutoDock Vina. Results: Gt-BuOH inhibited MCF-7 cells in a concentration- and time-dependent manner (2.0 ± 0.2% to 75.0 ± 0.3% at 72 h; IC₅₀ = 431.8 µg/mL) with low toxicity towards HFF (IC₅₀ > 1000 µg/mL; selectivity index > 2.32). GC-MS identified methyl oleate (71.62% of total ion chromatogram area), propanoic anhydride, and methyl butyrate as the principal constituents; the profile is dominated by fatty-acid derivatives rather than phenolics. Gt-BuOH treatment was associated with reduced p-EGFR, TOP2A, and TNF-α levels in MCF-7 cells but not in HFF cells. Docking predicted weaker individual binding affinities for the three constituents than for reference inhibitors; no synergy or multi-target advantage is claimed. Conclusion: These preliminary findings support further investigation of Gt-BuOH as a source of fatty-acid-derived antiproliferative agents, but bioassay-guided fractionation, additional cell lines, and functional validation are required before any therapeutic claims can be made.
Authors
- Youssef Shakuri Yasin (ORCID: https://orcid.org/0000-0003-1433-1858)
- Waleed Khalid Ahmed (ORCID: https://orcid.org/0000-0002-7659-6336)
- S Shaker (ORCID: https://orcid.org/0000-0003-4200-2840)
- Ali Mala Khedir Galalaey
- Ahmed Mohsin Abdulkhadim
- Amjed Abbawe Salih
- Azal Hamoody Jumaa
- Amenh Mohammed Abdulrahman
Institutions
- University of Kirkuk (IQ)
- University Of Fallujah (IQ)
- Iraqi University (IQ)
- Bilad Alrafidain University College (IQ)
- Salahaddin University-Erbil (IQ)
- University of Tikrit (IQ)
Publication Details
- Journal
- Journal of cancer research updates
- Published
- 2026-11-14
- DOI
- https://doi.org/10.30683/1929-2279.2026.15.35
- Primary Topic
- Phytochemical Studies and Bioactivities
- Type
- article
- Field-Weighted Citation Impact
- 0.00